Actively Recruiting
Evaluating Safety and Preliminary Efficacy of CTx001 in Geographic Atrophy Secondary to Age-Related Macular Degeneration Using Single Subretinal Injection
Led by Complement Therapeutics · Updated on 2026-10-16
75
Participants Needed
8
Research Sites
213 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary efficacy of CTx001, a genetic therapy given via a single subretinal injection, in people with geographic atrophy GA caused by age-related macular degeneration AMD. This first in human Phase 12 study aims to determine how well CTx001 works and how safe it is for this eye condition. Participants will receive one of three dose levels of CTx001 in sequential cohorts. After the initial dosing, some participants may enter expansion phases with selected doses. The treatment is given once by subretinal injection, and safety and efficacy are monitored regularly up to 2 years. Long-term safety follow-up continues annually for up to 5 years after dosing. During the study, participants will undergo regular assessments including imaging to measure lesion size and retinal function, visual acuity tests, and evaluations of retinal sensitivity. Researchers will monitor safety and immune responses to the therapy. The primary outcome focuses on safety and tolerability through the first year, while secondary outcomes assess changes in the eyes structure and function for up to 2 years and long-term safety for 5 years. Total participation may last up to 5 years.
CONDITIONS
Brief Title
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Research Team
M
Muhammad Ali Memon
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here